Last update 15 Apr 2025

SIM-0686

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
SIM 0686, SIM0686
Target
FGFR2 x FGFR2b x Top I
Action
antagonists, inhibitors
Mechanism
FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR2b inhibitors(fibroblast growth factor receptor 2 IIIb inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
FGFR2 Mutation Solid TumorsSolid tumor
Inactive Indication-
Originator Organization
Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.
Active Organization
Shanghai Xianxiang Medical Technology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with SIM-0686
CTR20251415
/ Not yet recruitingPhase 1
一项在局部晚期/转移性实体瘤成年受试者中评价 SIM0686 的安全性、耐受性、药代动力学和初步抗肿瘤活性的开放性、多中心、首次人体 I 期研究
[Translation] An open-label, multicenter, first-in-human Phase I study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SIM0686 in adult subjects with locally advanced/metastatic solid tumors
100 Clinical Results associated with SIM-0686
Login to view more data
100 Translational Medicine associated with SIM-0686
Login to view more data
100 Patents (Medical) associated with SIM-0686
Login to view more data
100 Deals associated with SIM-0686
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FGFR2 Mutation Solid TumorsPhase 1
China
Shanghai Xianxiang Medical Technology Co., Ltd.
14 Apr 2025
Solid tumorPhase 1
China
Shanghai Xianxiang Medical Technology Co., Ltd.
14 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free